SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

14 Jun 2023 07:00

RNS Number : 6184C
Victrex PLC
14 June 2023
 
 

14 June 2023

Victrex plc - Trading update

Victrex plc is an innovative world leader in high performance polymer solutions, delivering sustainable products which support CO2 reduction and bring environmental and societal benefit in multiple end-markets. Today's trading update covers the period ending 31 May 2023.

Year-to-date (YTD) Group volume & revenue

At the Group's interim results we signalled that, in line with the wider Chemical sector, ongoing macro-economic weakness and industrial customer destocking were impacting performance in several end markets. During the first half, Group volumes declined by 14%.

Whilst the Group remains ready to benefit from a macro-economic recovery, latest indicators suggest these current headwinds will now continue over the summer and at least until the end of FY 2023 in September.

Despite good progress in Medical, ongoing industrial headwinds mean YTD Group volumes are now tracking in excess of 20% down, compared to the record prior year. YTD Group revenue is tracking down by a mid-single digit percentage rate. If current run-rates continue, full year revenue would be down between 6%-10%.

For Q3 as a whole, we anticipate volumes will be approximately 800 tonnes (Q3 2022: 1,323 tonnes).

Outlook

In our Outlook at the interim results stage, we signalled that delivering full-year adjusted (pre-exceptional) profit before tax (PBT) in line with expectations assumed a step up in demand during the latter part of the second half, driven by macro-economic conditions.

Whilst we are seeing progress on gross margin, driven by pricing, sales mix, currency and easing energy costs, Group adjusted PBT to 31 May 2023 was approximately £53m. With no step up in demand going into the final quarter currently visible, and the resulting lower industrial revenue expectations, our full year adjusted PBT is now expected to be between £80m-£85m.  

Victrex will report its Q3 Interim Management Statement on Thursday 6 July 2023.

 

Analyst & investor conference call:

A conference call with management will take place this morning, 14 June 2023, at 08.00am BST. The call can be accessed via the following link:

 

https://services.choruscall.za.com/DiamondPassRegistration/register?confirmationNumber=2616372&linkSecurityString=6aee7987c

 

Inside information:

This announcement contains inside information. The person responsible for making this announcement is Jane Brisley, General Counsel & Company Secretary.

 

Enquiries:

Victrex plc:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG +44 (0) 7809 595831

Jakob Sigurdsson, Chief Executive +44 (0) 1253 897700

Ian Melling, Chief Financial Officer +44 (0) 1253 897700

 

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, provide environmental and societal benefit for customers and drive value for our shareholders. Find out more at www.victrexplc.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTGPUAAQUPWPGW
Date   Source Headline
29th May 202611:00 amRNSTotal Voting Rights
18th May 20268:50 amRNSDirectorate change
11th May 20267:00 amRNSHalf-year Financial Report
30th Apr 202610:46 amRNSTotal Voting Rights
29th Apr 20264:28 pmRNSHolding(s) in Company
31st Mar 20261:37 pmRNSTotal Voting Rights
24th Mar 20264:29 pmRNSHolding(s) in Company
24th Mar 20262:03 pmRNSHolding(s) in Company
20th Mar 20269:38 amRNSHolding(s) in Company
27th Feb 20262:40 pmRNSTotal Voting Rights
27th Feb 20261:02 pmRNSHolding(s) in Company
24th Feb 202611:41 amRNSHolding(s) in Company
17th Feb 20263:06 pmRNSDirector/PDMR Shareholding
12th Feb 20263:26 pmRNSDirector/PDMR Shareholding
12th Feb 20263:22 pmRNSDirector/PDMR Shareholding
10th Feb 20262:43 pmRNSDirector/PDMR Shareholding
10th Feb 20269:00 amRNSDirectorate change
6th Feb 20261:33 pmRNSResult of AGM
6th Feb 20267:00 amRNSQ1 Trading Update
30th Jan 202611:49 amRNSTotal Voting Rights
28th Jan 202612:25 pmRNSHolding(s) in Company
22nd Jan 202610:21 amRNSHolding(s) in Company
20th Jan 20261:26 pmRNSAdditional Listing
31st Dec 20259:00 amRNSTotal Voting Rights
31st Dec 20259:00 amRNSTotal Voting Rights
22nd Dec 202512:00 pmRNSAnnual Financial Report
22nd Dec 202512:00 pmRNSAnnual Financial Report
18th Dec 202511:49 amRNSDirector/PDMR Shareholding - Replacement
17th Dec 20253:42 pmRNSDirector/PDMR Shareholding
17th Dec 202512:08 pmRNSDirector/PDMR Shareholding
15th Dec 20259:00 amRNSDirector/PDMR Shareholding
11th Dec 20258:52 amRNSDirector/PDMR Shareholding
5th Dec 20259:30 amRNSShare purchase by incoming Director (incoming CEO)
4th Dec 20259:06 amRNSFinancial Calendar Update
2nd Dec 20257:00 amRNSPreliminary Results
1st Dec 202510:49 amRNSBlock listing Interim Review
28th Nov 20259:27 amRNSTotal Voting Rights
20th Nov 20259:05 amRNSAdditional Listing
7th Nov 202510:39 amRNSHolding(s) in Company
31st Oct 20258:58 amRNSTotal Voting Rights
21st Oct 20257:30 amRNSCEO Succession update
3rd Oct 202511:36 amRNSHolding(s) in Company
3rd Oct 20259:03 amRNSHolding(s) in Company
30th Sep 20259:54 amRNSTotal Voting Rights
29th Aug 202510:16 amRNSTotal Voting Rights
31st Jul 20259:14 amRNSTotal Voting Rights
9th Jul 20251:02 pmRNSHolding(s) in Company
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.